Abstract
BackgroundPatients with autoimmune rheumatic diseases are at higher risk of cardiovascular complications and premature mortality[1,2], possibly related to chronic inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
